LLBO owns 47% Cyrcadia Health (skip to par 4)
Calculation LLBO PPS Est .22
(It’s a journey so stay with me)
EBITDA PPS valuation for small/midsize CO’s. is 5-7x earnings. EBITDA(Earnings before interest taxes depreciation and amortization)
Let’s Compute PPS using the above commonly used securities formula:
Cyrcadia Health CH
Cyrcadia Asia
CA
~40 Million Mammograms not including other breast screenings per yr USA, not including the rest of the world.
But, (Asia breast cancer screening market size is expected to cross over US $4 Billion by 2022, @ US ~avg cost $100ea this equals 40 million Asian breast screenings annually). iT Bra to begin Asia Dist this January. If CA iTBra gets 10% of that Mkt ((current female population of Asia is 2,550,000,000
BILLION (say what!)
49.6 % of women population is urban, median age is 31—4Mil iTBras no problem)) = 4,000,000mil users x $150= $600Mil revenue ((CA iTBra-12 scans uploaded per yr for a total annual cost of ~$150 info provided by CA)) & avg gross EBITDA profit of 45% (600x.45)=
$270Mil at 5X that profit =(270x 5)= $1.350 Billion Cyrcadia Asia value).
USA value is equivalent given equal market comparison, so (1.35+1.35)=
$2.7 Billion combined CH/CA value using EBITDA standards @ 5x earnings (Not 7x), & most recent Co. data released.
(That’s the big picture, & the one I believe the Mkt will react to given my past experience)
So LLBO PPS:
LLBO owns 47% of CH ...So
CH Val including CA% ownership (per Fin. Info released & some Algebra is
1.35Bil CH +103Mil (2.5%)CA = $1.453Bil total CH value, so LLBO .47 x 1.453=
$683 Mil LLBO value.
Stay with me now
So 683/3.1bil shares O/S =
LLBO stock price of $.22 PPS USA & Asia only.
(No S Amer., Europe, Russia, Australia...)
In addition Cyrcadia Health & Cyrcadia Asia jointly own Cyrcadia Data Services Ltd (iTBra data input) Cyrcadia Asia also has equity shares of Cyrcadia Health adding further value to the 2.5% listed above.
Total Company & affiliates est value
CH $26 PPS ~27Mil shares O/S
CA $51 PPS ~34Mil sharesO/S
LLBO $.22 ~3.1
Bill shares O/S
Above numbers only include USA & Asia (no Europe, Russia,etc) the world wide market expenditure on breast cancer is ~ One “Trillion” US Dollars $1 Trillion
(Now obviously something as big as breast cancer & the need for alternative solutions, not to mention the —-“only” ——present way to get into the upcoming product launch is “LLBO stock” & don’t take that lightly.
Share price could fluctuate to higher levels on speculative value & it’s my personal opinion they will. I leave it up to the market as to where speculative PPS goes ?
(iTBra has FDA clearance)
(All of the above information was derived by using readily available breast cancer research information. Cyrcadia Inc released public financial info., iTBra target selling prices recently released & info such as CH CA % ownership, CA issued shares to CH, CA owned shares of CH, LLBO CH share holdings, applied mathematics & other info.
As PPS valuation is never an exact science I did my best to use hard data with as little speculation as possible IE: For instance what woman would not want to beat 1:8 odds of getting invasive breast cancer? Think of how many lottery tickets you’d buy with those odds. Thus my speculative 10% of breast screening market for PPS valuation ! (Hell, don’t like 10% use 2% still a hell of a PPS)
Also, Keep in mind the iTBra is not going to reduce the breast screening market
I merely use breast screening & statistics as a fixed point as it’s hard data.
GLTA
Cyrcadia, Inc. – 2017 Year End and 2018 Look Forward Newsletter
| Feb 21, 2018 |
——Exert——
“The intent is to launch into both the consumer and Over the Counter (OTC) markets almost simultaneously with the clinical markets. Thus far, indications are favorable for this approach and we will be meeting directly with the FDA in the months to come, declaring our intent. We will report again on the meeting outcomes once definitive. Moreover, CI will pursue a Modified 510(k) through the FDA enabling the rapid expansion of the clinical markets. This does not preclude us from going to market with our existing 510(k), Class II clearance (see the NFJ position above), but will certainly enhance our visibility and buy-in from the medical/clinical community.
On behalf of the Cyrcadia, Inc. team, we thank you for your support as we bring this life saving technology to market. We will make every effort to ensure timely and profitable delivery of CI’s technology to the U.S. market and rest of world outside of the territories covered by CA.
Sincerely,
Matt Benardis
CEO
Cyrcadia Health
“How brands are using AI and VR to boost health care and predict trends”
BY DIANE YOUNES
20 SEP 2018
——-Exerpt——
Lau is keeping a close eye on a specific start-up, which is using AI to link fashion and health care.
For Asian women, our biology and size means that the current standard of mammography is not as accurate as it needs to be.
“What Cyrcadia is doing with AI and breast cancer detection is a game-changer.”
Have a good Thanksgiving &
HO HO HO Merry Christmas, Happy Holidays & Happy Any other Holiday Celebrated by all ...to all !
:>)And to the negatives out there, piles of smiles :)
LLBO Est PPS .22
Lifeline Biotechnologies
USA/Asia valuation, not including Europe, Russia, Australia, S America...
(The .22 takes into consideration of Lifelines 47% equity share of Cyrcadia Incorporated as well as percentage ownership of Cyrcadia Asia & Cyrcadia Asia’s stock ownership of Cyrcadia Health.)
Details in previous post...
News 
Market Data 
Discover 
AI
